A practical introduction to pharmaceutical regulatory affairs, covering what the function does, how medicines move through regulatory systems, the agencies involved, and how professionals build careers in the field.

Learn more about our full regulatory affairs training courses – here

 

What Is Pharmaceutical Regulatory Affairs?

Pharmaceutical regulatory affairs is the function responsible for ensuring that medicines are developed, manufactured, assessed, approved, and maintained in line with applicable laws and regulatory expectations. In simple terms, it is the discipline that helps translate scientific innovation into approved medicines that can safely reach patients.

That sounds straightforward, but the role is much broader than many people realise. Regulatory affairs is not just about filling in forms or checking whether a document complies with a guideline. It is a strategic function that sits between science, compliance, and business. It takes complex development work from research, preclinical studies, clinical trials, manufacturing, and labelling, then turns it into regulatory submissions and decisions that health authorities can review. At the same time, it helps companies make informed decisions about where to file, when to file, how much data is needed, and what the likely risks are.

Regulatory affairs is a strategic integrator. That is a useful phrase because it captures the reality of the job. Regulatory affairs does not operate in isolation. It connects research and development, CMC, clinical, quality, pharmacovigilance, medical affairs, commercial teams, and senior management. It helps ensure that products are developed responsibly, approved efficiently, and maintained safely throughout their lifecycle. It also helps ensure that medicines reach patients as quickly as possible without compromising quality, safety, or efficacy.

So when people ask, “What is pharmaceutical regulatory affairs?”, the best answer is this: it is the discipline that makes medicine development and approval possible in the real world.

 

Why Pharmaceutical Regulatory Affairs Matters

Pharmaceutical development is expensive, slow, and highly regulated. A promising molecule can fail not only because it lacks efficacy or safety, but also because the development strategy was poorly aligned with regulatory expectations. That is where regulatory affairs becomes critical.

A strong regulatory affairs function matters because it helps organisations:

• understand which regulatory pathway applies to a product
• generate the right data at the right time
• avoid unnecessary studies and delays
• secure approvals for clinical trials and marketing authorisations
• maintain compliance after approval
• adapt to changing regulations and scientific standards

 

Regulatory affairs is not only about public health protection, although that is central. It is also essential to business success. Choosing the right pathway can help products reach the market earlier. Understanding what regulators expect can avoid costly rework. Knowing how to position a dossier can affect approval timelines and lifecycle opportunities. In that sense, regulatory affairs is both a public health function and a commercial enabler.

This is also why regulatory affairs professionals are often involved in strategic conversations much earlier than people assume. They are not just brought in at the point of submission. The good ones are involved when companies are deciding what product they have, which markets they want to target, what studies they need, and how they can reduce regulatory risk.

For a complementary look at how the role stretches across development and commercialisation, see your related article:

 

The Role of Regulatory Affairs Across the Product Lifecycle

Regulatory affairs supports medicines throughout their entire lifecycle—from early development through to post-approval maintenance. Its core role is to ensure that products are developed in line with regulatory expectations, approved efficiently, and maintained in compliance once on the market.

At a high level, regulatory affairs:

• Defines development and regulatory strategy early
• Supports clinical trial applications and authority interactions
• Leads marketing authorisation submissions
• Manages post-approval changes and compliance

 

The key point is that regulatory affairs is not a single-stage function—it is continuously involved, adapting its focus as a product moves from concept to commercialisation.

For a full breakdown across each phase, see:
👉 https://educolifesciences.com/what-regulatory-affairs-professionals-do-across-the-product-lifecycle/

 

Key Regulatory Agencies in Pharmaceutical Regulatory Affairs

Regulatory affairs professionals must understand the agencies that assess medicines and shape the frameworks in which companies operate. The EU and US systems are not structured in the same way.

The European System: A Multilayered Framework (Shortened)

Unlike the United States, the European regulatory system is not managed by a single authority. Instead, it operates as a coordinated network of EU-level institutions and national agencies, each with defined responsibilities.

European Medicines Agency (EMA)

The EMA is responsible for the scientific evaluation of medicines, particularly under the centralised procedure. It coordinates expert committees and provides regulatory guidance.

European Commission

The European Commission issues the final legally binding marketing authorisation, based on the EMA’s scientific opinion.

National authorities and coordination groups

National agencies remain central to decentralised and mutual recognition procedures and contribute expertise to EU-level assessments.

This multi-layered approach enables collaboration across member states, but also adds complexity compared to more centralised systems.

For a deeper explanation of EU approval pathways and how they work in practice:
👉 https://educolifesciences.com/navigating-eu-marketing-authorisation/

 

The United States: a centralised FDA model

The US system is more centralised. The Food and Drug Administration (FDA) is the key regulatory authority. The FDA is described as responsible for reviewing and approving INDs, NDAs, and BLAs, as well as conducting inspections, handling pharmacovigilance, reviewing promotional materials and prescribing information, and issuing guidance and enforcement actions.

Within FDA, different centres handle different product types:

• CDER: mainly small molecules and generics
• CBER: biologics and vaccines
• other centres support devices and diagnostics

 

This centralised structure means that, compared with Europe, the US often offers a more unified decision-making model. The EU has a more collaborative, multilayered system than the US’s single federal agency approach.

That FDA element is important because a true introduction to pharmaceutical regulatory affairs should not present the discipline as EU-only. For many companies, products are developed with both EU and US expectations in mind from quite an early stage.

 

Submission Types in Pharmaceutical Regulatory Affairs

Another core part of understanding pharmaceutical regulatory affairs is understanding the main submission types professionals work with.

 

Clinical trial submissions

In Europe, companies submit a Clinical Trial Application (CTA). The clinical trial regulation simplified the earlier fragmented model by allowing one online application through the Clinical Trials Information System for multinational EU trials. That means sponsors can submit more efficiently across multiple countries, with greater harmonisation than under the earlier directive system.

In the US, the equivalent key development-stage submission is the Investigational New Drug application (IND). The IND is the formal request to FDA for permission to test a new drug or biologic in humans. It is there to ensure that the proposed clinical trial does not expose humans to unreasonable risk, that the investigational product is manufactured consistently and safely, and that the study design and investigator qualifications are scientifically and ethically sound.

There are several types of IND:

• commercial IND
• research investigator IND
• emergency IND
• expanded access treatment IND

 

That detail matters because it shows that the US framework is not just one static pathway; it is adaptable depending on who is sponsoring the work and why.

 

How the FDA IND process works

The training gives useful practical detail on the FDA process. Often companies begin with a pre-IND meeting to discuss data requirements and trial design. They then submit the IND electronically, including preclinical, manufacturing, and clinical information. FDA has a 30-day safety review period. If FDA does not object within those 30 days, the sponsor may begin the trial. The agency can allow the trial to proceed, place it on clinical hold, or ask for clarification or additional data. Amendments, new sites, safety reports, and annual reports then form part of IND maintenance.

That FDA material belongs in this article because it shows how regulatory affairs supports not only approvals but also the controlled entry into human development.

 

Marketing authorisation submissions

Once sufficient development data exists, regulatory affairs coordinates the application for product approval.

In the EU, this is the Marketing Authorisation Application (MAA).

In the US, two major approval routes:

• NDA for traditional chemically synthesised drugs, often small molecules
• BLA for biologics such as monoclonal antibodies, vaccines, cell-based therapies, gene therapies, and recombinant proteins

The FDA review timelines are often described as 10 months from filing date, though filing itself follows an initial review period, while priority review may reduce that to 6 months from filing. This is one of the reasons the US can sometimes appear faster than the EU centralised review model.

 

Post-approval change submissions

Regulatory affairs also handles changes after approval.

In the EU, those are generally managed through variations, such as Type IA, IB, and II, depending on the significance of the change. In the US, there are supplemental applications, including prior approval supplements, changes being effected pathways, and annual reportable changes. Major changes require approval before implementation, while lower-risk changes may be reported or implemented under more flexible rules.

This is another reason regulatory affairs remains important after launch: medicines rarely stay completely static once commercialised.

 

The Common Technical Document and Why It Matters

The Common Technical Document (CTD) is the standard format used globally to organise and present data in regulatory submissions. It provides a structured way for companies to demonstrate the quality, safety, and efficacy of a medicinal product.

The CTD is divided into five modules:

• Module 1: Administrative and regional information
• Module 2: Summaries and expert overviews
• Module 3: Quality (CMC)
• Module 4: Nonclinical data
• Module 5: Clinical data

 

For regulatory affairs professionals, the CTD is more than just a format—it is the framework that brings together cross-functional data into a coherent submission. In particular, the summaries and overviews in Module 2 play a critical role in interpreting the data and clearly communicating the product’s benefit–risk profile to regulators.

For a deeper, practical breakdown of each module and how the CTD is used in submissions:
👉 https://educolifesciences.com/a-short-guide-to-the-ich-ctd/

 

Career Pathways in Pharmaceutical Regulatory Affairs

Pharmaceutical regulatory affairs offers a structured and progressive career path, typically moving from operational support roles into strategic leadership positions.

Early roles focus on supporting submissions and documentation, while more senior positions involve defining regulatory strategy, leading cross-functional teams, and engaging directly with health authorities.

As experience grows, professionals often move into global roles or leadership positions overseeing regulatory strategy across multiple products or regions.

If you’re exploring entry routes, skills, and progression in more detail:
👉 https://educolifesciences.com/how-to-start-a-career-in-eu-regulatory-affairs/

 

Conclusion: Pharmaceutical Regulatory Affairs as a Strategic Discipline

Pharmaceutical regulatory affairs is much more than a gatekeeping or paperwork function. It is the discipline that helps ensure medicines are developed correctly, evaluated properly, and maintained responsibly throughout their lives on the market.

It works across science, compliance, and business. It supports early development decisions, clinical trial approvals, marketing authorisation submissions, post-approval changes, and regulatory strategy across regions. It requires an understanding of both the EU’s multilayered agency structure and the US FDA’s centralised model. And it creates meaningful career opportunities for professionals who want to work at the intersection of science and decision-making.

Written by Educo Life Sciences Expert, Adriaan Fruijtier

Adriaan Fruijtier graduated as a pharmacist at the University of Utrecht, The Netherlands. Since April 2004 he has been an independent regulatory affairs consultant. Until March 2004 he was Head of the Oncology Group within Global Regulatory Affairs at Bayer AG, Wuppertal, Germany, and Bayer Corporation, West Haven, CT, USA. Between 2001 and 2003 he was Director of Regulatory Affairs at Micromet AG, a biotech company in Munich, Germany. Prior to joining Micromet he has worked during four years as a Project Manager for Oncology Projects at the European Medicines Agency in London, United Kingdom. He joined the European Medicines Agency from Novartis AG, Basel, Switzerland, where he was Regulatory Affairs Project Manager in the Oncology group in 1996 and 1997. Before 1996 he was Head of Drug Regulatory Affairs for six years at Ciba-Geigy in the Netherlands and has worked as Manager of Regulatory Affairs at Glaxo, also in the Netherlands.

This article was written using materials from the course, Understanding EU Regulatory Affairs.